Von Willebrand disease 3
MONDO:0010191Type 3 von Willebrand disease (type 3 VWD) is the most severe form of VWD characterized by a bleeding disorder associated with a total or near-total absence of Willebrand factor (von Willebrand factor; VWF) in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII (FVIII).
Also known as: VWD3, von Willebrand disease 3, von Willebrand disease type 3, von Willebrand's disease 3, von Willebrand's disease type 3, VON WILLEBRAND disease, type 3, VWD, type 3, Von Willebrand disease, type 3
22 clinical trials for this condition and its sub-types, 9 tagged with Von Willebrand disease 3 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug aims to stop bleeds in rare blood disorder
Disease control Recruiting nowThis study tests a medicine called emicizumab to prevent bleeding episodes in people with Type 3 von Willebrand disease, a severe inherited bleeding disorder. About 75 participants, from infants to adults, will receive either emicizumab or continue their current treatment. The go…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for bleeding disorder: first human trial of HMB-002 begins
Disease control Recruiting nowThis study tests a new medicine, HMB-002, in about 108 adults with von Willebrand disease (types 1 and 2). The goal is to check safety, how the drug moves in the body, and whether it helps control bleeding. It is the first time this drug is being tested in humans, starting with s…
Phase 1/2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a simple shot replace IV treatments for severe bleeding disorder?
Disease control Recruiting nowThis study tests whether emicizumab (Hemlibra), a medicine given as a shot under the skin, can safely prevent bleeding in people with severe von Willebrand disease (VWD) or combined VWD/hemophilia A. About 40 participants of any age (including infants) will receive the drug and b…
Phase 1 • Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New study tracks bleeding in von willebrand disease to pave way for better treatments
Knowledge-focused Recruiting nowThis study is for people aged 16 to 70 with von Willebrand disease (VWD), a bleeding disorder. Researchers will collect information on bleeding events, treatments, and quality of life over time. The goal is to understand the real-world impact of VWD and use this data as a baselin…
Sponsor: Hemab ApS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New registry aims to unlock secrets of rare bleeding disorder
Knowledge-focused Recruiting nowThis study creates a web-based registry for people with severe von Willebrand disease (sVWD), a rare bleeding disorder. Researchers will collect information from up to 400 participants about their medical history, symptoms, and lab results. The goal is to build a detailed databas…
Sponsor: VWD Connect Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC